← Archive

The Riptide Beneath the Wave: Why OBBBA Splits the Maternal Health Market in Two

The doula category raised more than $30M in a single quarter on the strength of Medicaid reimbursement momentum — but the One Big Beautiful Bill Act's October 2026 implementation creates real rollback risk for the state doula Medicaid benefits that made that thesis investable.

---

The Foundation the Wave Was Built On

Three weeks ago we mapped the Q1 2026 doula funding wave: Nadia Care, Malama Health, and Flourish Care together raised $30.9M in a single quarter, the most concentrated cluster of doula investment on record. The thesis converged on a clean proposition — community-based doulas, Medicaid reimbursement, outcomes data strong enough to make an actuary nod — and for a brief moment it looked like a category had arrived.

It has. The complication is the ground it arrived on.

The reimbursement infrastructure that made these companies fundable was built in a specific policy window. Since 2019, more than 30 states created some form of Medicaid doula reimbursement, with California, Oregon, Minnesota, and New Jersey leading. Federal maternal health provisions directed CMS to support state community health worker expansions. Medicaid managed care organizations, sensing the cost-avoidance math on NICU utilization and preterm births, began contracting proactively. The window opened, and three well-built companies stepped through it.

The One Big Beautiful Bill Act, signed July 4, 2025, introduces the most significant structural pressure on that window since it opened. Its Medicaid provisions — work and reporting requirements for able-bodied adults, six-month eligibility redeterminations for ACA expansion adults starting October 1, 2026, and restrictions on coverage for lawfully present immigrants — are projected by the CBO to leave 7.8 million people uninsured. Among those people: reproductive-age women in exactly the population demographic that doula companies serve.

The mechanism matters. OBBBA doesn't eliminate doula benefits directly. What it does is tighten state Medicaid budgets, redirect administrative capacity toward coverage verification, and create a fiscal environment in which optional benefits — including doula reimbursement, which requires a state legislative or regulatory decision to adopt and maintain — face the kind of scrutiny that discretionary line items face in a budget crunch. Doula Medicaid reimbursement is not a mandate in most states. It is a policy choice, and policy choices are reversible when budgets are under pressure.

A Georgetown Center for Children and Families report released April 1 adds state-level specificity to this risk: certain states with large lawfully present immigrant populations face particularly acute postpartum coverage exposure, and the administrative churn from new eligibility verification requirements creates de facto coverage gaps even for families who remain technically eligible. Pregnant people and caregivers are exempt from work requirements — but they still have to prove it, in a system not famous for its exemption processing speed.

The question for every Medicaid-dependent maternal health company is not whether OBBBA matters. It is how exposed they are, and what levers they have to respond.

---

Who Wins the Channel Bifurcation

The investor narrative about "Medicaid as a market" is correct — the clinical need is concentrated in Medicaid populations, outcomes data is most compelling in that cohort, and the cost-avoidance math works best against the costs that Medicaid MCOs bear. But Medicaid as a market has always come with a second sentence: it is a market whose economics are set by governments, not buyers, and which requires each state to decide independently to pay for new benefit categories.

OBBBA's October 2026 implementation is creating a channel bifurcation that was already forming in slower motion. Here is what it looks like in practice:

The employer channel is not a substitute for Medicaid access — the population that benefits most from doula care is disproportionately covered by Medicaid, not by employer plans. The commercial channel serves a different, more affluent population, and companies that pivot entirely toward it leave their founding mission behind. The architecture that actually works — the Maven Clinic and Carrot Fertility playbook that Flourish is executing — keeps one foot in the Medicaid mission and one foot in the commercial channel, using each to fund the other. OBBBA doesn't destroy that model. It makes it necessary.

---

What Happens Next (and Who Holds the Cards)

The October 2026 implementation date is a deadline with a 60-day window that will tell us a great deal about which states are protecting maternal health coverage and which are not.

States with recent doula Medicaid reimbursement expansions and progressive maternal health track records — California, Minnesota, Oregon, New Jersey — are most likely to absorb OBBBA pressure without rolling back doula benefits. They have state-level advocates, active MCO relationships, and legislative history that makes benefit rollback politically costly. Companies concentrated in these states are reasonably insulated.

States with more fiscally constrained budgets, weaker maternal health legislative infrastructure, or large lawfully present immigrant populations facing eligibility restrictions — Texas, Georgia, Mississippi, certain Plains states — are higher risk. For doula companies operating in these markets, the question is how quickly they can move revenue toward commercial and employer channels, or whether they can accelerate contracting with MCOs on a capitated or shared-savings basis that insulates revenue from per-service reimbursement rate changes.

UnitedHealthcare's employer doula expansion, announced March 16, is the largest structural piece of the employer channel opening up. Seven-point-two million employer members gaining access to doula benefits by January 2027 is not a niche signal — it is a major commercial payer making a category mainstream. The clinical evidence UHC cited to justify the expansion (50% lower preterm birth rates, 58% fewer low-birth-weight infants, 35% lower NICU utilization in its Medicaid pilot) is the same actuarial argument the category has been building toward for years. UHC made it with its own data. That is a category arrival moment regardless of what Medicaid does next.

The strategic question UHC's expansion raises for doula platform companies is distribution: does The Doula Network partnership structure, through which UHC is sourcing its employer benefit, crowd out other doula platforms from the employer channel — or does a rising tide float multiple platforms? If UHC's Doula Network partnership is exclusive for employer benefit sourcing, Flourish Care, Malama Health, and Partum Health need to build their own employer distribution relationships independently. If it isn't, there is room for platform differentiation within the employer benefit category.

Pomelo Care's trajectory is the most important adjacent signal. At a $1.7B valuation with 25 million covered lives, a documented 37% reduction in preterm births, and a stated expansion from maternity into pediatrics, Pomelo is building the platform that acquires or partners with best-in-class point solutions in the maternal health stack. A doula network acquisition would give Pomelo a community-based care layer that cannot be replicated with technology alone. Seed valuations are attractive for a company at Pomelo's scale. The moment to transact is before OBBBA implementation tightens Medicaid revenue and complicates earnout structures.

The maternal health market is not collapsing. The need is not going away, the outcomes data is not softening, and the employer channel is expanding. What October 2026 changes is the risk profile of Medicaid dependence — and the premium placed on companies that anticipated that this day would come.

---

What We're Watching

• Which states signal rollback intent before October 1. State legislative sessions in Q2 2026 are the leading indicator. A budget proposal that eliminates or reduces doula Medicaid reimbursement in Texas, Georgia, or Ohio would move from policy risk to revenue reality — and would clarify exactly which of the doula platforms is most exposed.
• Whether UHC's Doula Network employer partnership is structured exclusively. The answer determines whether Q4 2026 employer benefits season is a rising-tide opportunity for all doula platforms or a UHC-sourced consolidation that walls off the commercial channel. Expect this to become clearer as UHC begins employer plan enrollment processes in fall 2026.
• Pomelo Care's M&A appetite in the maternal support stack. Pomelo's Series C materials, its SMFM research on preterm birth reduction, and its stated expansion into pediatrics all point toward an integrated maternal-to-pediatric care model that needs a community health worker layer. A doula platform acquisition in the next 12–18 months would confirm the thesis and set valuations for the rest of the category.

---